Pacharapan SurapolchaiSuradej HongengPat MahachoklertwattanaSamart PakakasamaAngkana WinaichatsakNittaya WisanuyothinEkawat PasomsubSurakameth MahasirimongkolNongnuch SirachainanMahidol UniversityFaculty of Medicine, Thammasat UniversityMaharaj Nakhon Ratchasima HospitalThailand Ministry of Public Health2018-09-242018-09-242010-07-01Journal of Pediatric Hematology/Oncology. Vol.32, No.5 (2010), 383-38915363678107741142-s2.0-77955883063https://repository.li.mahidol.ac.th/handle/20.500.14594/29615Aim/Purpose: Survivors of acute lymphoblastic leukemia (ALL) are at increased risks of impaired glucose metabolism, insulin resistance, and metabolic syndrome. The aim of our study was to determine the prevalence of alterations in glucose metabolism and the predisposing factors of these disturbances in survivors of childhood ALL. Patients and methods: in 131 ALL survivors, an oral glucose tolerance test was conducted to determine β-cell function/insulin sensitivity. The particular risk factors were analyzed and 6 single nucleotide polymorphisms of diabetic predisposing genes: PAX4 and TCF7L2 were genotyped to evaluate the association between these factors and β-cell function/insulin sensitivity. Results: Ten out of 131 survivors (7.6%) had impaired glucose tolerance (IGT) whereas 40 out of 131 (30.5%) had insulin resistance (IR) and showed characteristics of the metabolic syndrome (hyperinsulinemia, hypertriglyceridemia, and low HDL-C). in the logistic regression analysis, the most important factor predicting IGT and IR was older age of survivors (p = 0.014 and P < 0.001, respectively) whereas the PAX4 R192H mutation (rs2233580) was significantly associated with IGT after adjustment for age (P = 0.043) (adjusted OR 5.28, 95% CI 1.06-26.40). Conclusions: Existing evidence suggests that older age is an independent risk factor for developing IGT and IR in childhood ALL survivors, emphasizing the need for life-long metabolic screening. The PAX4 variant might impact individual susceptibility against IGT and diabetes. However, an identification of underlying risk(s) is the rational for future studies. Copyright © 2010 by Lippincott Williams & Wilkins.Mahidol UniversityMedicineArticleSCOPUS10.1097/MPH.0b013e3181dccc0b